Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 147.42

+1.7%

Dec 22 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: fred hayes who wrote (1612)	6/24/2006 12:03:37 PM
From: Icebrg	Read Replies (1) of 1834

>>I'm still puzzled by the timing of pfe's pullout.>> I believe the only explanation that makes sense is what Lyons said at the cc. It was a portfolio question, as far as PFE is concerned. Evidently they felt that 5 and 10 mg IR formulation plus the 15 mg MR would not generate the turnover/profit they are looking for. Especially since NBIX was also supposed to have a nice cut of the cake too. I don't believe that they have an agreement (with whom?) to buy Sepracor. There was anyhow no reason to kill Indiplon before they had Lunesta in the bag. Losing the higher MR formulations killed the product as far as PFE is concerned. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next